Madrigal Pharmaceuticals Stock Performance
| MDGL Stock | USD 478.83 9.43 1.93% |
The company secures a Beta (Market Risk) of 0.77, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Madrigal Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Madrigal Pharmaceuticals is expected to be smaller as well. At this point, Madrigal Pharmaceuticals has a negative expected return of -0.0887%. Please make sure to verify Madrigal Pharmaceuticals' downside variance, day median price, and the relationship between the treynor ratio and kurtosis , to decide if Madrigal Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Madrigal Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent technical and fundamental indicators, Madrigal Pharmaceuticals is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors. ...more
Actual Historical Performance (%)
One Day Return (1.93) | Five Day Return (0.01) | Year To Date Return (19.37) | Ten Year Return 7.1 K | All Time Return 50.5 |
Last Split Factor 1:35 | Dividend Date 2016-07-25 | Last Split Date 2016-07-25 |
1 | Disposition of 2500 shares by Levy Richard S of Madrigal Pharmaceuticals at 7.36 subject to Rule 16b-3 | 11/13/2025 |
2 | Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635 | 11/20/2025 |
3 | Disposition of tradable shares by Carole Huntsman of Madrigal Pharmaceuticals at 564.565 subject to Rule 16b-3 | 11/21/2025 |
4 | Madrigal Pharmaceuticals Rezdiffras Strong Launch Spurs Rethink of Blockbuster Potential and Current Valuation | 12/05/2025 |
5 | Madrigal Pharmaceuticals Is Up 5.4 percent After REZDIFFRA Phase 3 Data And CFO Hire - Has The Bull Case Changed | 12/22/2025 |
6 | Disposition of 1560 shares by Friedman Paul A of Madrigal Pharmaceuticals at 526.9685 subject to Rule 16b-3 | 01/02/2026 |
7 | Disposition of 18410 shares by Taub Rebecca of Madrigal Pharmaceuticals at 15.8 subject to Rule 16b-3 | 01/09/2026 |
8 | Disposition of 840 shares by Friedman Paul A of Madrigal Pharmaceuticals at 521.9779 subject to Rule 16b-3 | 01/13/2026 |
9 | Disposition of 2238 shares by Taub Rebecca of Madrigal Pharmaceuticals at 490.77 subject to Rule 16b-3 | 01/20/2026 |
10 | Madrigal Pharmaceuticals Lobbying And Insider Sales Put Valuation In Focus | 01/27/2026 |
11 | CCORF Maintains Madrigal Pharmaceuticals With Buy Rating, Maintains Target Price 587 - | 01/29/2026 |
| Begin Period Cash Flow | 99.9 M | |
| Total Cashflows From Investing Activities | -274.4 M | |
| Free Cash Flow | -457 M |
Madrigal Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 51,493 in Madrigal Pharmaceuticals on November 13, 2025 and sell it today you would lose (3,610) from holding Madrigal Pharmaceuticals or give up 7.01% of portfolio value over 90 days. Madrigal Pharmaceuticals is currently does not generate positive expected returns and assumes 2.5757% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Madrigal, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Madrigal Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Madrigal Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 478.83 | 90 days | 478.83 | about 92.01 |
Based on a normal probability distribution, the odds of Madrigal Pharmaceuticals to move above the current price in 90 days from now is about 92.01 (This Madrigal Pharmaceuticals probability density function shows the probability of Madrigal Stock to fall within a particular range of prices over 90 days) .
Madrigal Pharmaceuticals Price Density |
| Price |
Predictive Modules for Madrigal Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Madrigal Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Madrigal Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Madrigal Pharmaceuticals is not an exception. The market had few large corrections towards the Madrigal Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Madrigal Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Madrigal Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.03 | |
β | Beta against Dow Jones | 0.77 | |
σ | Overall volatility | 42.78 | |
Ir | Information ratio | -0.02 |
Madrigal Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Madrigal Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Madrigal Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Madrigal Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 180.13 M. Net Loss for the year was (465.89 M) with profit before overhead, payroll, taxes, and interest of 705.49 M. | |
| Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (455.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38. | |
| Madrigal Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635 |
Madrigal Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Madrigal Stock often depends not only on the future outlook of the current and potential Madrigal Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Madrigal Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 21.3 M | |
| Cash And Short Term Investments | 926.3 M |
Madrigal Pharmaceuticals Fundamentals Growth
Madrigal Stock prices reflect investors' perceptions of the future prospects and financial health of Madrigal Pharmaceuticals, and Madrigal Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Madrigal Stock performance.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.39) % | ||||
| Operating Margin | (0.40) % | ||||
| Current Valuation | 10.33 B | ||||
| Shares Outstanding | 22.71 M | ||||
| Price To Earning | (13.96) X | ||||
| Price To Book | 17.72 X | ||||
| Price To Sales | 14.97 X | ||||
| Revenue | 180.13 M | ||||
| Gross Profit | 705.49 M | ||||
| EBITDA | (450.12 M) | ||||
| Net Income | (465.89 M) | ||||
| Cash And Equivalents | 211.77 M | ||||
| Cash Per Share | 12.38 X | ||||
| Total Debt | 119.57 M | ||||
| Debt To Equity | 0.59 % | ||||
| Current Ratio | 2.55 X | ||||
| Book Value Per Share | 27.56 X | ||||
| Cash Flow From Operations | (455.57 M) | ||||
| Earnings Per Share | (12.89) X | ||||
| Market Capitalization | 11.09 B | ||||
| Total Asset | 1.04 B | ||||
| Retained Earnings | (1.8 B) | ||||
| Working Capital | 863.65 M | ||||
| Current Asset | 363.58 K | ||||
| Current Liabilities | 49.28 M | ||||
About Madrigal Pharmaceuticals Performance
By examining Madrigal Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Madrigal Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Madrigal Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.8 K | 1.6 K | |
| Return On Tangible Assets | (0.52) | (0.54) | |
| Return On Capital Employed | (0.66) | (0.69) | |
| Return On Assets | (0.51) | (0.54) | |
| Return On Equity | (0.71) | (0.67) |
Things to note about Madrigal Pharmaceuticals performance evaluation
Checking the ongoing alerts about Madrigal Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Madrigal Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Madrigal Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 180.13 M. Net Loss for the year was (465.89 M) with profit before overhead, payroll, taxes, and interest of 705.49 M. | |
| Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (455.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38. | |
| Madrigal Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635 |
- Analyzing Madrigal Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Madrigal Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Madrigal Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Madrigal Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Madrigal Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Madrigal Pharmaceuticals' stock. These opinions can provide insight into Madrigal Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. Expected growth trajectory for Madrigal significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Madrigal Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (12.89) | Revenue Per Share | Quarterly Revenue Growth 3.62 | Return On Assets | Return On Equity |
Investors evaluate Madrigal Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Madrigal Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Madrigal Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Madrigal Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Madrigal Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Madrigal Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.